Antitumor activity of cryptophycins: Effect of infusion time and combination studies

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 2, 2000, Pages 142-149

  Menon, K ^a   Alvarez, E ^a   Forler, P ^a   Phares, V ^a   Amsrud, T ^a   Shih, C ^a   Al Awar, R ^a   Teicher, B A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cryptophycin 52; Cryptophycins; Microtubulin inhibitors

Indexed keywords

CISPLATIN; CRYPTOPHYCIN 52; CRYPTOPHYCIN DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; COMPLEX FORMATION; DRUG EFFECT; INFUSION; MEMBRANE TRANSPORT; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0033891960     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000135     Document Type: Article

References (34)

1. Characterization of the interaction of cryptophycin 1 with tubulin: Binding in the vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction
2. Preclinical anti-cancer activity of cryptophycin-8
3. Absence of HeLa cell contamination in 169 cell lines derived from human tumors
4. L-Dopa decarboxylase activity (DDC): A distinguishing biomarker for the growth of small cell lung cancer (SCLC) in tissue culture
5. Effects of dibutyral cyclic adenosine 3',5'-monophosphate on the growth of cultured human small cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase
6. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological and growth properties
7. Antimitotic natural products and their interactions with tubulin
8. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
9. Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults
10. Antitumor principles derived from vinca rosea Linn: I. Vinca leuoblastine and leurosine
11. Vinorelbine: An overview
12. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy
13. Interaction of cryptophycin 1 with tubulin and microtubules
14. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site
15. Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent
16. Mechanism of action of the unusually potent microtubule inhibitor, cryptophycin 1
17. Preclinical antitumor activity of cryptophycin-52/55 (C-52;C-55) against human tumors in SCID mice
18. The development and Clinical utility of the taxane class of microtubule chemotherapy agents
19. Binding of the epoxide cryptophycin analog, LY355703, to albumin and its effects on in vitro antiproliferative activity
20. Pharmaceuticals from cultured algae
21. Mechanism of action of cryptophycin
22. Cryptophycin: A new microtubule agent active against drug-resistant cells
23. Phase I trial of the cryptophycin analogue LY355703 administered as an IV infusion, D1 and D8, repeated every 21 days
24. Approaches to defining the mechahism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity
25. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination
26. Oxygenation of the rat 9L gliosarcoma and the rat 13762 mammary carcinoma with various doses of a hemoglobin solution
27. Administration of a hemoglobin solution decreases hypoxia and increases radiation response in a rat mammary carcinoma
28. Total structures of cryptophycins, potent antitumor desipeptides from the blue-green algae Nostoc sp. Strain GSV
29. In vitro pharmacology of LY355703 (cryptophycin 52), in human tumor cell lines
30. The mechanism of action of cryptophycin 52 (LY355703): Cellular effects on human colon carcinoma cell lines HT-29 and Caco-2
31. Pharmacological probes of microtubule function
32. Microtubule dynamics: Taking aim at a moving target
33. LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts